Zacks Investment Research Downgrades Genmab A/S (OTCMKTS:GNMSF) to Hold
According to Zacks, “Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company’s product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. “
GNMSF opened at $205.74 on Wednesday. The stock has a fifty day moving average of $184.31 and a 200-day moving average of $172.70. The firm has a market capitalization of $12.61 billion, a P/E ratio of 64.09 and a beta of 0.17. Genmab A/S has a 12-month low of $119.10 and a 12-month high of $205.74.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.